Hennion & Walsh Asset Management Inc. Has $6.18 Million Position in Ardelyx, Inc. $ARDX

Hennion & Walsh Asset Management Inc. raised its position in Ardelyx, Inc. (NASDAQ:ARDX) by 21.0% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,211,690 shares of the biopharmaceutical company’s stock after purchasing an additional 210,209 shares during the period. Hennion & Walsh Asset Management Inc. owned approximately 0.49% of Ardelyx worth $6,180,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Ardelyx by 2.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 159,061 shares of the biopharmaceutical company’s stock valued at $781,000 after buying an additional 4,436 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in Ardelyx by 10.3% during the first quarter. Goldman Sachs Group Inc. now owns 2,378,738 shares of the biopharmaceutical company’s stock worth $11,680,000 after acquiring an additional 221,486 shares in the last quarter. Focus Partners Wealth bought a new position in Ardelyx during the first quarter worth about $72,000. Strs Ohio acquired a new position in Ardelyx in the first quarter valued at about $135,000. Finally, Legal & General Group Plc increased its holdings in shares of Ardelyx by 13.5% in the second quarter. Legal & General Group Plc now owns 275,344 shares of the biopharmaceutical company’s stock worth $1,080,000 after acquiring an additional 32,738 shares in the last quarter. 58.92% of the stock is owned by institutional investors.

Trending Headlines about Ardelyx

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Second-quarter revenue increased 34.3% year over year to approximately $120.9 million, indicating continued commercial growth despite missing the revenue estimate slightly. Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: BTIG Research maintained a Buy rating on ARDX, suggesting substantial long-term upside potential even after reducing its price target from $17 to $14. BTIG Research price target update
• Neutral Sentiment: Ardelyx’s Q2 earnings call and business update provided additional discussion of operating performance and company priorities, but the available report does not identify a specific new catalyst driving the stock. Ardelyx Q2 2026 Earnings Call Transcript
• Negative Sentiment: Ardelyx reported a second-quarter loss of $0.07 per share, worse than the expected loss of $0.05, although it improved from a $0.08 loss in the year-ago quarter. Revenue of $120.88 million also narrowly missed estimates of approximately $121.0 million. Ardelyx Reports Q2 Loss, Lags Revenue Estimates
• Negative Sentiment: Zacks added ARDX to its Rank #5, or Strong Sell, list, adding to near-term pressure from the earnings miss and the company’s continuing negative profitability metrics. New Strong Sell Stocks for August 7th
• Negative Sentiment: The lower BTIG price target reflects reduced near-term expectations, even though the firm retained its Buy rating. BTIG Research price target update

Analysts Set New Price Targets

ARDX has been the subject of a number of research analyst reports. TD Cowen reduced their price objective on shares of Ardelyx from $13.00 to $10.00 and set a “buy” rating for the company in a research report on Friday. HC Wainwright restated a “buy” rating and set a $13.00 target price on shares of Ardelyx in a research note on Friday. Zacks Research downgraded shares of Ardelyx from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 22nd. LADENBURG THALM/SH SH initiated coverage on shares of Ardelyx in a research note on Tuesday, June 16th. They issued a “buy” rating and a $16.00 price target on the stock. Finally, BTIG Research cut their price objective on shares of Ardelyx from $17.00 to $14.00 and set a “buy” rating for the company in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.30.

Ardelyx Stock Performance

ARDX stock opened at $4.00 on Monday. Ardelyx, Inc. has a 52 week low of $3.90 and a 52 week high of $8.40. The company has a market capitalization of $996.76 million, a PE ratio of -18.18 and a beta of 0.70. The company’s 50-day simple moving average is $5.37 and its 200 day simple moving average is $6.07. The company has a debt-to-equity ratio of 1.37, a quick ratio of 3.28 and a current ratio of 3.49.

Ardelyx (NASDAQ:ARDX) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The business had revenue of $120.88 million during the quarter, compared to analyst estimates of $121.03 million. Ardelyx had a negative return on equity of 35.57% and a negative net margin of 12.35%.Ardelyx’s revenue for the quarter was up 34.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.08) EPS. As a group, sell-side analysts anticipate that Ardelyx, Inc. will post -0.1 earnings per share for the current year.

Insider Activity at Ardelyx

In related news, insider Mike Kelliher sold 7,248 shares of the business’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $6.27, for a total value of $45,444.96. Following the completion of the sale, the insider directly owned 357,418 shares in the company, valued at approximately $2,241,010.86. The trade was a 1.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Eric Duane Foster sold 7,998 shares of the stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $6.27, for a total value of $50,147.46. Following the sale, the insider directly owned 417,972 shares in the company, valued at $2,620,684.44. This represents a 1.88% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 24,572 shares of company stock worth $154,066 over the last ninety days. Insiders own 5.30% of the company’s stock.

About Ardelyx

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.